The startup develops cell-based immunotherapy platforms that enhance the efficacy and safety of existing cell and gene therapies. By optimizing cellular modifications and delivery mechanisms, the company enables clients to achieve better therapeutic outcomes and patient responses.
Funding
Funding not disclosed
Founders
Product
Problem
Current cell and gene therapies face challenges in efficacy and safety due to immune rejection, suboptimal gene delivery, limited cell expansion, and insufficient tumor targeting. Existing methods often require complex gene editing or result in high production costs, hindering the development of effective and scalable cell-based immunotherapies.
Solution
Vycellix develops a suite of cell therapy engineering solutions designed to enhance and optimize cell and gene-based therapies. The company's platforms address key limitations in cell therapy manufacturing and efficacy, including immune rejection, gene transduction efficiency, cell expansion rates, and multi-antigen engagement. By leveraging technologies such as its VY-UC universal cell platform, VY-OZ transduction enhancer, VY-M cell expansion reagent, and VY-GAGE multi-antigen engager, Vycellix enables the development of more effective, safer, and scalable allogeneic cell therapies. These tools can be integrated into existing cell therapy workflows to improve cell persistence, reduce manufacturing costs, and enhance tumor targeting.
Target Audience
Vycellix's primary customers are cell and gene therapy companies, research institutions, and clinical organizations focused on developing and manufacturing allogeneic cell-based immunotherapies for cancer and other diseases.
Features
- **VY-UC (Universal Cells):** A single-step CD45 allogeneic cell engineering platform that prevents immune synapse formation, generating immune-privileged cells and eliminating the risk of graft rejection without complex gene editing.
- **VY-OZ (Cell Transduction):** A small molecule that enhances gene transduction into cytotoxic lymphocytes and hematopoietic stem cells using viral vectors, improving gene editing rates for CRISPR-based systems by transiently downregulating intracellular anti-viral defense mechanisms.
- **VY-X (Cell Potency):** A non-coding RNA construct that increases the efficacy of cytotoxic cellular therapies by increasing the density of perforin and granzyme B in effector cells, resulting in higher serial killing.
- **VY-M (Cell Expansion):** An ex vivo cell manufacturing reagent that optimizes the proliferation of T cells, NK cells, and other cells, decreasing non-dividing lag time and shortening vein-to-vein delivery time.
- **VY-GAGE (Multi-Antigen Engagement):** A peptide capable of delivering multiple disease-targeting payloads specifically to tumor sites, including BiKEs and CARs, to enhance tumor targeting and minimize off-target effects.